Guidelines for African swine fever (ASF) vaccines: field evaluation and post-vaccination monitoring
African swine fever (ASF) is a devastating transboundary disease affecting domestic and wild pigs, with major consequences for pig production, animal health systems and safe trade worldwide. Commercially produced live attenuated virus (LAV) vaccines for ASF control have recently received regulatory approval in Southeast Asian countries, but robust evidence on their performance in the field remains limited. These are the first international guidelines for the field evaluation and post-vaccination monitoring of ASF vaccines. They were developed for the World Organisation for Animal Health (WOAH) by the Applied Epidemiology Group at The Pirbright Institute and the Centre for Applied One Health Research and Policy Advice at City University of Hong Kong. The WOAH Ad hoc Group on Guidelines for ASF contributed, with experts from the Pan African Veterinary Vaccine Centre of the African Union (AU-PANVAC), the WOAH Scientific Commission for Animal Diseases, the Bureau of Animal Industry of the Philippines Department of Agriculture, the WOAH ASF Reference Laboratory Network, the Food and Agriculture Organization of the United Nations (FAO), the University of Minnesota College of Veterinary Medicine, the European Medicines Agency and Vietnam National University of Agriculture. The guidelines provide a technical reference for Veterinary Services and competent authorities, covering the design, implementation and evaluation of field studies, as well as the benefit risk assessment that should precede any national or regional vaccination programme. They also address systematic tracking of vaccine effectiveness under real world conditions, alongside pharmacovigilance to detect side effects or adverse events. The guidelines stress that only high quality vaccines manufactured according to international standards should be used, and that vaccination should form part of a comprehensive ASF control strategy and cannot replace traditional prevention measures. Throughout, transparency and data sharing are presented as essential to evidence-based decision-making.